Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (325)	8/3/2005 6:53:56 PM
From: ddl	Read Replies (1) \| Respond to of 377

<i."2nd chf pt's are terminal. the vsgn treatment - if it works at all, is a bandaid, it does not "save lives" or "cure" the patient"" How can you say "If it works at all" when the facts bluntly contradict your statement. PII CHF has a 7:1 ratio of survivors over placebo. Even if it is a small population, that is obviously a drastic result. Are you playing with me here?

To: Pluvia who wrote (325)	8/3/2005 7:39:31 PM
From: Clarksterh	Read Replies (1) \| Respond to of 377

1st. not enough pt's for statistical significance; 2nd chf pt's are terminal. the vsgn treatment - if it works at all, is a bandaid, it does not "save lives" or "cure" the patient Tsk, tsk. Not really fair. Just trying to win the argument by any means. a) It was stat sig for death (if I remember correctly) b) So, terminal patients aren't deserving of anything? Wow, look at all of those cancer trials. What a waste of money. The Vasogen ph ii's do have a lot of weaknesses (I've listed many on the yahoo board), but the above are not they. Clark